Currently, BioNTech SE ADR [BNTX] is trading at $111.48, up 4.85%. An important factor to consider is whether the stock is rising or falling in short-term value. The BNTX shares have gain 4.54% over the last week, with a monthly amount drifted -5.15%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
BioNTech SE ADR [NASDAQ: BNTX] stock has seen the most recent analyst activity on November 08, 2024, when Goldman upgraded its rating to a Buy and also boosted its price target to $137 from $90. Previously, Morgan Stanley upgraded its rating to Overweight on September 24, 2024, and elevated its price target to $145. On September 17, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $150 on the stock. JP Morgan upgraded its rating to a Neutral and increased its price target to $125 on September 16, 2024. Deutsche Bank upgraded its rating to a Buy but $95 remained the price target by the analyst firm on August 07, 2024. HSBC Securities upgraded its rating to Buy for this stock on August 02, 2024. In a note dated May 14, 2024, Evercore ISI initiated an In-line rating and provided a target price of $100 on this stock.
This stock has fluctuated between a low of $76.53 and a high of $131.49 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $163.29 within the next 12 months. BioNTech SE ADR [NASDAQ: BNTX] shares were valued at $111.48 at the most recent close of the market. An investor can expect a potential return of 46.47% based on the average BNTX price forecast.
Analyzing the BNTX fundamentals
Trailing Twelve Months sales for BioNTech SE ADR [NASDAQ:BNTX] were 3.30B which represents 40.41% growth. Gross Profit Margin for this corporation currently stands at 0.64% with Operating Profit Margin at -0.32%, Pretax Profit Margin comes in at -0.09%, and Net Profit Margin reading is -0.19%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.03 and Total Capital is -0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 107.11 points at the first support level, and at 102.75 for the second support level. However, for the 1st resistance point, the stock is sitting at 114.52, and for the 2nd resistance point, it is at 117.57.
Ratios To Look Out For
To put it in perspective, the Current Ratio for BioNTech SE ADR [NASDAQ:BNTX] is 7.33. On the other hand, the Quick Ratio is 7.21, and the Cash Ratio is 4.28. Considering the valuation of this stock, the price to sales ratio is 8.10, the price to book ratio is 1.25.
Transactions by insiders
Recent insider trading involved Tureci Ozlem, Officer, that happened on Nov 12 ’24 when 0.56 million shares were purchased. 10% Owner, ATHOS KG completed a deal on Oct 16 ’24 to buy 8036.0 shares. Meanwhile, 10% Owner ATHOS KG bought 25424.0 shares on Oct 14 ’24.
